Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: August 13, 2022

Details for Patent: 5,948,818

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 5,948,818
Title: Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Abstract:Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).
Inventor(s): Buser; Thomas (Ziefen, CH), Camporesi; Emilio P. (Ziefen, CH)
Assignee: Tillotts Pharma AG (Ziefen, CH)
Application Number:09/069,751
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Use;

Drugs Protected by US Patent 5,948,818

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,948,818

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9509764May 15, 1995

International Family Members for US Patent 5,948,818

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 294575 See Plans and Pricing
Australia 5895596 See Plans and Pricing
Australia 702692 See Plans and Pricing
Brazil 9608785 See Plans and Pricing
Canada 2221356 See Plans and Pricing
China 1104237 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.